Evidence map›Paper›PMID 35620389›Full record

ReviewFrontiers in endocrinology2022

Nonthyroidal Illness Syndrome: To Treat or Not to Treat? Have We Answered the Question? A Review of Metanalyses.

Salvatore Sciacchitano, Carlo Capalbo, Christian Napoli, Paolo Anibaldi, Valentina Salvati, Claudia De Vitis, Rita Mancini, Flaminia Coluzzi, Monica Rocco

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Review
  5. Article
  6. Mechanisms and Prognostic Assessment Value of Thyroid Hormone in Liver Failure.Journal of clinical and translational hepatology · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Salvatore SciacchitanoDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Carlo CapalboUnit of Medical Oncology, Sant'Andrea University Hospital, Rome, Italy.
Christian NapoliDepartment of Surgical and Medical Science and Translational Medicine, Sapienza University of Rome, Rome, Italy.
Paolo AnibaldiHealth Management Director, Sant'Andrea University Hospital, Rome, Italy.
Valentina SalvatiScientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Claudia De VitisDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Rita ManciniDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Flaminia ColuzziUnit of Anesthesia, Intensive Care and Pain Medicine, Sant'Andrea University Hospital, Rome, Italy.
Monica RoccoDepartment of Surgical and Medical Science and Translational Medicine, Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · ITIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objective: Nonthyroidal Illness Syndrome (NTIS) occurs in approximately 70% of patients admitted to Intensive Care Units (ICU)s and has been associated with increased risk of death. Whether patients with NTIS should receive treatment with thyroid hormones (TH)s is still debated. Since many interventional randomized clinical trials (IRCT)s were not conclusive, current guidelines do not recommend treatment for these patients. In this review, we analyze the reasons why TH treatment did not furnish convincing results regarding possible beneficial effects in reported IRCTs. Methods: We performed a review of the metanalyses focused on NTIS in critically ill patients. After a careful selection, we extracted data from four metanalyses, performed in different clinical conditions and diseases. In particular, we analyzed the type of TH supplementation, the route of administration, the dosages and duration of treatment and the outcomes chosen to evaluate the results. Results: We observed a marked heterogeneity among the IRCTs, in terms of type of TH supplementation, route of administration, dosages and duration of treatment. We also found great variability in the primary outcomes, such as prevention of neurological alterations, reduction of oxygen requirements, restoration of endocrinological and clinical parameters and reduction of mortality. Conclusions: NTIS is a frequent finding in critical ill patients. Despite several available IRCTs, it is still unclear whether NTIS should be treated or not. New primary endpoints should be identified to adequately validate the efficacy of TH treatment and to obtain a clear answer to the question raised some years ago.

Indexed as

Euthyroid Sick SyndromesCritical IllnessHospitalizationHumansIntensive Care UnitsThyroid HormonesThyroid Hormonesbioelectrical impedance analysishydrationnonthyroidal illness syndromeSARS-CoV-2 (2019-nCoV) coronavirussodium/potassium exchangeable ratio

Identifiers

PMID35620389
PMCPMC9128382
OpenAlexW4229444721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.